Natixis Advisors LLC Invests $306,000 in R1 RCM Inc. (NASDAQ:RCM)

Natixis Advisors LLC purchased a new stake in R1 RCM Inc. (NASDAQ:RCM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,589 shares of the healthcare provider’s stock, valued at approximately $306,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Boston Partners raised its stake in shares of R1 RCM by 4,976.6% in the first quarter. Boston Partners now owns 2,570,371 shares of the healthcare provider’s stock valued at $32,784,000 after purchasing an additional 2,519,739 shares in the last quarter. Empyrean Capital Partners LP bought a new position in R1 RCM in the 2nd quarter valued at $26,376,000. Tokio Marine Asset Management Co. Ltd. acquired a new stake in shares of R1 RCM in the 3rd quarter valued at $11,986,000. Engine Capital Management LP boosted its holdings in R1 RCM by 96.0% in the second quarter. Engine Capital Management LP now owns 1,348,664 shares of the healthcare provider’s stock valued at $16,939,000 after acquiring an additional 660,428 shares during the last quarter. Finally, Troluce Capital Advisors LLC increased its position in R1 RCM by 373.7% in the second quarter. Troluce Capital Advisors LLC now owns 790,555 shares of the healthcare provider’s stock worth $9,929,000 after purchasing an additional 623,655 shares during the period. Institutional investors own 61.10% of the company’s stock.

R1 RCM Stock Performance

NASDAQ RCM opened at $14.31 on Friday. The business has a 50-day moving average price of $14.24 and a 200-day moving average price of $13.51. The firm has a market cap of $6.04 billion, a price-to-earnings ratio of -95.39 and a beta of 0.84. R1 RCM Inc. has a twelve month low of $8.87 and a twelve month high of $15.12. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.76.

R1 RCM (NASDAQ:RCM) last issued its quarterly earnings data on Tuesday, November 5th. The healthcare provider reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). The firm had revenue of $656.80 million for the quarter, compared to analysts’ expectations of $640.93 million. R1 RCM had a negative net margin of 2.48% and a negative return on equity of 2.18%. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. As a group, equities research analysts predict that R1 RCM Inc. will post -0.18 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Leerink Partners lowered R1 RCM from an “outperform” rating to a “market perform” rating and cut their target price for the company from $17.00 to $14.30 in a research note on Thursday, August 1st. Truist Financial decreased their price objective on R1 RCM from $16.00 to $14.30 and set a “hold” rating for the company in a report on Thursday, August 8th. Jefferies Financial Group cut shares of R1 RCM from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $14.30 price target on shares of R1 RCM in a report on Friday, October 4th. Finally, TD Cowen reiterated a “hold” rating and set a $14.30 target price (down previously from $20.00) on shares of R1 RCM in a research note on Monday, August 5th. Thirteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.41.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.